Diagnostic Accuracy of Golgi Protein 73 (GP73) for Liver Fibrosis Staging in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Scoping Review and Cohort Study DOI Creative Commons
V.L. Pecoraro, Fabio Nascimbeni, Michela Cuccorese

et al.

Diagnostics, Journal Year: 2025, Volume and Issue: 15(5), P. 544 - 544

Published: Feb. 24, 2025

Background/Objectives: Golgi protein 73 (GP73) is a transmembrane expressed by epithelial cells of the bile duct in normal liver. High serum levels GP73 have been detected patients with acute or chronic liver diseases, MASLD, and its measurement has suggested as potential biomarker for fibrosis staging. We evaluated utility diagnosis MASH, Methods: performed literature scoping review to map current evidence about accuracy MASLD. searched Medline EMBASE English studies reporting an AUC value diagnosing MASLD MASH evaluating A narrative synthesis was conducted. Moreover, we observational study including 84 which 60 were biopsy-confirmed different stages, 15 healthy controls. Serum determined using chemiluminescent assay reported mean standard deviation (SD). Sensitivity (SE), specificity (SP), area under receiver operating characteristic (AUROC) curve, optimal cut-off calculated. Data considered statistically significant when p < 0.05. Results: Available ability discriminate from simple steatosis distinguish at fibrotic but still scarce. Our experimental showed that 30 ± 12 ng/mL 32 higher than those control group (19 ng/mL), increasing stage F0 F4. significantly advanced controls no (p > 0.05). ROC analysis demonstrated had good diagnostic (AUROC 0.85; SE 90%; SP 73%), 0.75; 82%; SP64%), 0.7; 56%; 79%) better other biomarkers diseases. Conclusions: could support clinicians evaluation fibrosis.

Language: Английский

Diagnostic Accuracy of Golgi Protein 73 (GP73) for Liver Fibrosis Staging in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Scoping Review and Cohort Study DOI Creative Commons
V.L. Pecoraro, Fabio Nascimbeni, Michela Cuccorese

et al.

Diagnostics, Journal Year: 2025, Volume and Issue: 15(5), P. 544 - 544

Published: Feb. 24, 2025

Background/Objectives: Golgi protein 73 (GP73) is a transmembrane expressed by epithelial cells of the bile duct in normal liver. High serum levels GP73 have been detected patients with acute or chronic liver diseases, MASLD, and its measurement has suggested as potential biomarker for fibrosis staging. We evaluated utility diagnosis MASH, Methods: performed literature scoping review to map current evidence about accuracy MASLD. searched Medline EMBASE English studies reporting an AUC value diagnosing MASLD MASH evaluating A narrative synthesis was conducted. Moreover, we observational study including 84 which 60 were biopsy-confirmed different stages, 15 healthy controls. Serum determined using chemiluminescent assay reported mean standard deviation (SD). Sensitivity (SE), specificity (SP), area under receiver operating characteristic (AUROC) curve, optimal cut-off calculated. Data considered statistically significant when p < 0.05. Results: Available ability discriminate from simple steatosis distinguish at fibrotic but still scarce. Our experimental showed that 30 ± 12 ng/mL 32 higher than those control group (19 ng/mL), increasing stage F0 F4. significantly advanced controls no (p > 0.05). ROC analysis demonstrated had good diagnostic (AUROC 0.85; SE 90%; SP 73%), 0.75; 82%; SP64%), 0.7; 56%; 79%) better other biomarkers diseases. Conclusions: could support clinicians evaluation fibrosis.

Language: Английский

Citations

0